Five-year Survival Rate of Bladder Cancer in Iran during 2001-2007

Abstract

Background & Objective: Bladder cancer is the fourth most common cancer in men and the most common cancer in women, comprising 8% of all males and 3% of female tumors. The present study aimed to estimate the five-year survival rates of bladder cancer in Iran. Methods: Information on 3,337 registered cases of bladder cancer was obtained from the Office of National Cancer Registry in the Ministry of Health and Medical Education (MOH & ME). A telephone survey was conducted to gather additional information, such as survival status, demographic, and clinical profile. Kaplan–Meier estimates of five-year survival rates were calculated according to the age of diagnosis, gender, pathological type, and provincial pole. Results and Conclusion: Overall five-year survival rate was 77%. According to the pathologic type, five-year survival rates were 81%, 66%, 81%, 42%, 77%, and 82% in low-grade urothelial carcinoma, high-grade urothelial carcinoma, adenocarcinoma, undifferentiated carcinomas, Squamous Cell Carcinomas (SCCs), and other tumors, respectively. Additionally, those tumors were 93%, 88%, 81%, 64%, and 44% among patients whose average ages at diagnosis were < 50, 50–59, 60–59, 70–79, and > 80 years old, respectively. Our study revealed that age and histological type were the major prognostic factors for survival in patients with bladder cancer. Therefore, given the histologic features of the tumor and patients with advanced age, a continuous screening would be highly warranted.

Non-invasive detection of bladder cancer via microfluidic immunoassay of the protein biomarker NMP22

“…3 The 5 year survival rate for BC patients in stage 0, stage 1, stage 2, and stage 3 are around 96%, 70%, 36%, and 5%, respectively. 4,5 Early diagnosis signicantly improves BC patient survival rates and reduces the cost and complexity of cancer treatment. 6 Currently, cystoscopy-aided imaging as a primary diagnosis means that BC is invasive and expensive.…”

Accuracy of Paris 2016 System for Non-invasive Diagnosis Bladder Malignancy

“…Easy accessibility, non-invasiveness, high sensitivity and specificity for high-grade urothelial cancers and excellent impact on the evaluation of the entire urinary tract have led to the use of this method. This method can detect high-grade malignant cells in occult cancers that are not detectable by cystoscopy ( 8 - 9 ). Positive cytology is significantly associated with tumor recurrence and is independent of other pathoclinical variables.…”

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma

“…Table 4 depicts the presented statistics regarding the bladder cancer prevalence in Iran [ 28 ] . According to a study conducted in Iran from 2001 to 2007, the survival rate of the low-grade and high-grade urothelial cell carcinomas was 81% and 66%, respectively [ 29 ] . Malignant cell carcinoma as another kind of this tumor is divided into two general categories: invasive (to muscle) and noninvasive bladder carcinoma.…”